or Try an Advanced Search...

    Technical Analysis for GDTC - CytoMed Therapeutics Limited

    Grade Last Price % Change Price Change
    C 2.23 0.90% 0.02
    GDTC closed up 9.99 percent on Wednesday, November 20, 2024, on 1.17 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical GDTC trend table...
    Date Alert Name Type % Chg
    Crossed Above 200 DMA Bullish 0.90%
    Crossed Above 50 DMA Bullish 0.90%
    Pocket Pivot Bullish Swing Setup 0.90%
    Outside Day Range Expansion 0.90%
    Wide Bands Range Expansion 0.90%
    Gapped Up Strength 0.90%
    Oversold Stochastic Weakness 0.90%
    200 DMA Resistance Bearish 10.98%
    50 DMA Resistance Bearish 10.98%
    MACD Bearish Centerline Cross Bearish 10.98%
    Older End-of-Day Signals for GDTC ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 2 hours ago
    60 Minute Opening Range Breakout about 2 hours ago
    Up 2% about 2 hours ago
    Up 1% about 3 hours ago
    Rose Above 10 DMA about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    GDTC Chart by TradingView
    Basic chart:

    Profile

    CytoMed Therapeutics Limited Description

    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapies Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical

    Is GDTC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
    Oct 24 Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
    Oct 7 CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
    Oct 4 CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine
    Oct 3 CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
    Oct 1 CytoMed Therapeutics Limited reports 1H results
    Sep 30 CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
    Sep 25 Presenting on the Emerging Growth Conference 75 Day 2 on September 26
    Aug 20 Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
    Jul 17 CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
    See more GDTC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.5
    52 Week Low 1.2
    Average Volume 14,990
    200-Day Moving Average 2.03
    50-Day Moving Average 2.06
    20-Day Moving Average 2.37
    10-Day Moving Average 2.22
    Average True Range 0.36
    RSI (14) 49.49
    ADX 33.84
    +DI 19.74
    -DI 12.20
    Chandelier Exit (Long, 3 ATRs) 2.48
    Chandelier Exit (Short, 3 ATRs) 2.91
    Upper Bollinger Bands 2.88
    Lower Bollinger Band 1.86
    Percent B (%b) 0.34
    BandWidth 42.72
    MACD Line -0.02
    MACD Signal Line 0.05
    MACD Histogram -0.0626
    Fundamentals Value
    Market Cap 25.48 Million
    Num Shares 11.5 Million
    EPS -0.28
    Price-to-Earnings (P/E) Ratio -7.89
    Price-to-Sales 50.45
    Price-to-Book 2.64
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.92
    Resistance 3 (R3) 2.88 2.62 2.80
    Resistance 2 (R2) 2.62 2.44 2.63 2.76
    Resistance 1 (R1) 2.41 2.33 2.52 2.45 2.72
    Pivot Point 2.15 2.15 2.20 2.16 2.15
    Support 1 (S1) 1.94 1.97 2.05 1.98 1.70
    Support 2 (S2) 1.68 1.86 1.69 1.66
    Support 3 (S3) 1.47 1.68 1.62
    Support 4 (S4) 1.51